Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).
Yazar
Isaacs, Claudine
O'Regan, Ruth
Andre, Fabrice
Toi, Masakazu
Jerusalem, Guy Heinrich Maria
Wilks, Sharon
Xu, Binghe
Masuda, Norikazu
Arena, Francis P.
Yardley, Denise Aysel
Yap, Yoon Sim
Mukhopadhyay, Pabak
Douma, Shyanne
El-Hashimy, Mona
Taran, Tanya
Sahmoud, Tarek
Lebwohl, David Edward
Gianni, Luca
Ozguroglu, Mustafa
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]